期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 66, 期 1, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01263-21
关键词
gepotidacin; pharmacokinetics; relative bioavailability; adolescents; safety
资金
- GlaxoSmithKline (Collegeville, PA, USA)
- Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority [HHSO100201300011C]
- GlaxoSmithKline
Gepotidacin is a promising novel antibiotic for antibiotic-resistant pathogens. Pharmacokinetic evaluations showed that its mesylate salt tablet formulation had good characteristics and was effective in both adults and adolescents. Safety profiles were similar between the two age groups.
Gepotidacin is a novel, first-in-class triazaacenaphthylene antibiotic that may provide a new treatment option for antibiotic-resistant pathogens. Two pharmacokinetic evaluations of oral gepotidacin are presented: a relative bioavailability study that guided formulation development, followed by an adult and adolescent study of the final formulation. In the relative bioavailability study, after gepotidacin administration to 26 healthy adults as free-base roller-compacted (RC) tablets, free-base high-shear wet granulation (HSWG) tablets, and mesylate salt reference capsules, the RC tablet exposure ratios and 90% confidence intervals (CIs) were within the 0.80-to-1.25 confidence bounds; however, the HSWG tablet maximum observed concentration (C-max) was higher than the reference (ratio, 1.15; 90% CI, 1.0113, 1.3047). In the healthy adult (n = 16) and adolescent (n = 17) study, a gepotidacin mesylate salt tablet was evaluated as a 1,500-mg single dose or 2 doses administered 6 or 12 h apart (6,000 mg total), or placebo was administered. The single-dose mean C-max was similar to 27% higher in adolescents than in adults, and area under the concentration-time curve (AUC) values were comparable in both populations. After 2 doses were administered, the mean C-max values were similar for both age groups, and the mean AUC was similar to 35% higher in adolescents than in adults. Concentrations increased proportionally with dose. Safety-risk profiles were similar for both age groups. Across studies, the most common adverse events were gastrointestinal. Overall, the pharmacokinetics of the final gepotidacin mesylate salt tablet have been well characterized, enrollment of adolescents into the pivotal trials is supported, and dosing intervals were determined that should provide adequate exposures for microbiological efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据